ArticleVeterinary clinical pathology2025
Disintegrin-Like and Metalloprotease With Thrombospondin Type 1 Repeat Motifs 13 (ADAMTS13) Activity in 40 Healthy Dogs.
Article in Veterinary clinical pathology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundIn humans, deficiency of a disintegrin-like and metalloprotease with thrombospondin type 1 motifs, number 13 (ADAMTS13), a von Willebrand factor (vWF) cleaving protease, is an underlying mechanism for thrombosis. The role of ADAMTS13 in canine thromboembolic disease is largely unknown.
objectivesThe aims of this study were to evaluate plasma ADAMTS13 activity in healthy adult dogs using a commercially available human ADAMTS13 activity ELISA kit and to establish its reference interval (RI).
methodsForty healthy adult dogs were prospectively enrolled. Normal health status was confirmed using physical examination findings, history, and the results of hemogram, biochemical profile, screen test for vector-borne diseases, and urinalysis. Plasma ADAMTS13 activity was assessed using the Diapharma RUO Technozym ADAMTS13 Activity ELISA. The assay's precision, accuracy, and detection limits were also evaluated.
resultsThe canine reference population was comprised of 21 spayed females, 14 castrated males, 3 intact females, and 2 intact males. The median plasma ADAMTS13 activity in healthy dogs was 0.76 IU/mL (range 0.45-1.04). The RI lower limit was 0.45 IU/mL (90% confidence interval 0.45-0.47). The upper limit, although calculated (1.04 IU/mL, 90% CI 1.04-1.04), likely does not reflect the true RI upper limit but a technical limitation of the assay; therefore, rendering an RI of > 0.45 IU/mL. The intra- and inter-assay precision and accuracy range were 9.6%, 11.5%, -8.8% to 3.4%, respectively.
conclusionsThe commercially available human ADAMTS13 activity ELISA kit was suitable to analyze canine samples, and the RI for adult dogs was established.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.